Rhein: an anthraquinone that modulates superoxide anion production from human neutrophils

M. Mian, S. Brunelleschi, S. Tarli, A. Rubino, D. Benetti, R. Fantozzi, L. Zilletti

Research output: Contribution to journalArticlepeer-review

Abstract

Rhein (4,5‐dihydroxyanthraquinone‐2‐carboxylic acid), the active metabolite of diacetylrhein, which has been reported as an effective antirheumatic drug in man, inhibited superoxide anion production from human neutrophils challenged with N‐formylmethionyl‐leucyl‐phenylalanine (FMLP: IC50, 2 times 10−5M) and A23186 (IC50, 10−5M), but not with phorbol myristate acetate. In the same concentration range (10−6‐10−3M), the drug did not affect oxy‐radical production by a cell‐free hypoxanthine‐xanthine oxidase system and exerted weak inhibitory effects on FMLP‐evoked lysosomal enzyme release. Rhein inhibitory effects on neutrophil functioning may contribute to the overall therapeutic activity of the parent drug, diacetylrhein. 1987 Royal Pharmaceutical Society of Great Britain

Original languageEnglish
Pages (from-to)845-847
Number of pages3
JournalJournal of Pharmacy and Pharmacology
Volume39
Issue number10
DOIs
Publication statusPublished - Oct 1987
Externally publishedYes

Fingerprint

Dive into the research topics of 'Rhein: an anthraquinone that modulates superoxide anion production from human neutrophils'. Together they form a unique fingerprint.

Cite this